Gossamer Bio Inc.

05/06/2021 | Press release | Distributed by Public on 05/07/2021 00:53

Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC),[...]